The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
复制标题
右雷佐生作为心脏保护剂在蒽环类药物治疗中的当前和未来作用：专家小组审查
DOI：
--
复制
发表时间：
2003
影响因子：
3.6
通讯作者：
Patrizia Vici
中科院分区：
文献类型：
--
作者：
Sandra M. Swain;Patrizia Vici
本文总结了心脏病学家和肿瘤学家专家会议关于在蒽环类药物化疗中使用右雷佐生的观点。蒽环类药物诱导的心脏毒性仍然是一个主要的问题和治疗的新趋势（例如，蒽环类药物与其他药物的组合）将确保它仍然是一个问题。右雷佐生可降低患有一系列肿瘤类型的成人和儿童的心脏毒性。进一步的研究可能有助于确定那些特别有心脏毒性风险的患者以及从右雷佐生中受益最多的患者。右雷佐生在其他临床情况下也有许多可能性，必须在未来的试验中加以解决。
This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.
影响因子：
45.3
作者：
Krischer, JP;Epstein, S;Lipshultz, SE
通讯作者：
Lipshultz, SE
对晚期恶性肿瘤患者进行 96 小时连续输注右雷佐生的 I 期试验。
DOI：
--
发表时间：
2001
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research.
影响因子：
--
作者：
Tetef,ML;Synold,TW;Chow,W;Leong,L;Margolin,K;Morgan,R;Raschko,J;Shibata,S;Somlo,G;Yen,Y;Groshen,S;Johnson,K;Lenz,HJ;Gandara,D;Doroshow,JH
通讯作者：
Doroshow,JH